Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia

Bulletin of Mathematical Biology

Volumn 73, Issue 5, 2011, Pages 1082-1100

  Paquin, Dana ^a   Kim, Peter S ^b   Lee, Peter P ^c   Levy, Doron ^d  

^a CALIFORNIA POLYTECHNIC STATE UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Maryland   (United States)

Author keywords

Chronic myelogenous leukemia; Imatinib; Mathematical model; Strategic treatment interruptions

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALGORITHM; ARTICLE; BIOLOGICAL MODEL; CHRONIC MYELOID LEUKEMIA; COMPUTER SIMULATION; HUMAN; IMMUNOLOGY; LEUKOCYTE COUNT; PATHOLOGY; RECURRENT DISEASE; T LYMPHOCYTE; TIME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTE COUNT; MODELS, BIOLOGICAL; PIPERAZINES; PYRIMIDINES; RECURRENCE; T-LYMPHOCYTES; TIME FACTORS;

EID: 79953709746     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-010-9553-0     Document Type: Article

References (20)

1. Adams, B. M., Banks, H. T., Kwon, H.-D., & Tran, H. T. (2004). Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng., 1(2), 223-241.
2. Angstreich, G., Smith, B., & Jones, R. (2004). Treatment options for chronic myelogenous leukemia: imatinib versus interferon versus allogeneic transplant. Curr. Opin. Oncol., 16, 95-99.
3. Bajaria, S. H., Webb, G., & Kirschner, D. E. (2004). Predicting differential responses to structured treatment interruptions during HAART. Bull. Math. Biol., 66, 1093-1118.
4. Chen, C., Maecker, H., & Lee, P. (2008). Development and dynamics of robust T-cell responses to CML. Blood, 111(11), 5342-5349.
5. Cortes, J., Talpaz, M., O'Brien, S., Jones, D., Luthra, R. et al. (2005). Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res., 11, 3425-3432.
6. Dingli, D., & Michor, F. (2006). Successful therapy must eradicate cancer stem cells. Stem Cells, 24, 2603-2610.
7. Kim, P., Lee, P., & Levy, D. (2008). Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol., 4(6), e1000095.
8. Komarova, N., & Wodarz, D. (2005). Drug resistance in cancer: Principles of emergence and prevention. Proc. Natl. Acad. Sci., 102, 9714-9719.
9. Koup, R. (2004). Reconsidering early HIV treatment and supervised treatment interruptions. PLoS Med., 1(2), e41.
10. Lee, S. (2000). Chronic myelogenous leukemia. Br. J. Hematol., 111, 993-1009.
11. Lowenberg, B. (2003). Minimal residual disease in chronic myeloid leukemia. N. Engl. J. Med., 349, 1399-1401.
12. Maserati, R., Foli, A., Tomasoni, L., Sighinolfi, L., Maggiolo, F., Sacchini, D., DiPietro, M., Bertelli, D., Tinelli, C., & Lori, F. (2007). Effects of structured treatment interruptions on metabolic anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART. Curr. HIV Res., 5(3), 337-343.
13. McKay, M. D., Conover, W. J., & Beckman, R. J. (1979). A comparison of three models for selecting values of input variables in the analysis of output from a computer code. Technometrics, 21, 239-245.
14. Mahon, F., Rea, D., Guilhot, F., Legros, L., Guilhot, J., Aton, E., Dulucq, S., Reiffers, J., & Rousselot, P. (2009). Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial. J. Clin. Oncol., 27, 7084.
15. Michor, F., Hughes, T., Iwasa, Y., Branford, S., Shah, N., Sawyers, C., & Nowak, M. (2005). Dynamics of chronic myeloid leukemia. Nature, 435, 1267-1270.
16. Piazza, R., Magistroni, V., Franceschino, A., Andreoni, F., Tornaghi, L. et al. (2006). The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol. Dis. 37, 111-115.
17. Roeder, I., & Glauche, I. (2008). Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia-insights from mathematical model analyses. J. Mol. Med., 86, 17-27.
18. Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M. et al. (2006). Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical applications. Nat. Med., 12, 1181-1184.
19. Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M. et al. (2007). Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109, 58-60.
20. Sawyers, C. (2000). Chronic myeloid leukemia. N. Engl. J. Med., 340, 1330-1340.